Table 1.
Summary of the OS and PFS of patients receiving different treatments and characterized by non-methylated and methylated MGMT promoters in different studies.
| References | Pathology | Treatment | OS (months) | PFS (months) | ||||
|---|---|---|---|---|---|---|---|---|
| MGMTm | MGMTu | All | MGMTm | MGMTu | ALL | |||
| Criniere et al. (28) | GBM | RT+BCNU | 17.1 (14.5–26.5) | 13.1 (10.1–17.2) | NG | NG | ||
| RT | 15.1 (9.8–n.r.) | 10.2 (3.33–21.9) | NG | |||||
ALL
|
14.4 (13–16.1) | 13.6 (11.4–15.7) | 13.9 (12.5–15.3) | 7.33 (5.8–8.43) | 7.63 (6.47–8.63) | 7.37 (6.5–8.43) | ||
| Hegi et al. (29) | GBM | RT+TMZ | 21.7 (17.4–30.4) | 12.7 (11.6–14.4) | NG | 10.3 (6.5–14.0) | 5.3 (5.0–7.6) | NG |
| RT | 15.3 (13.0–20.9) | 11.8 (9.7–14.1) | 5.9 (5.3–7.7) | 4.4 (3.1–6.0) | ||||
| ALL | 18.2 (15.5–22.0) | 12.2 (11.4–13.5) | NG | NG | ||||
| Reifenberger et al. (30) | GBM (age ≥ 70) | RT+TMZ | 13.1 (11.0–15.3) | 10.4 (8.4–12.4) | 12.3(11.2–13.4) | 7.3 (6.2–8.5) | 7.2 (5.6–8.7) | 7.2 (6.3–8.0) |
| TMZ | 7.2 (5.6–8.9) | 2.6 (n.r.) | 6.8(4.8–8.8) | 6.8 (2.5–11.0) | 0.5 (n.r.) | 5.3 (0.1–10.5) | ||
| RT | 7.8 (3.4–12.2) | 8.8 (7.5–10.1) | 8.7(7.0–10.4) | 4.5 (3.5–5.4) | 5.2 (4.3–6.2) | 5.0 (4.4–5.6) | ||
| No treatment | 2.3 (0.8–3.8) | 2.0 (0.6–3.7) | 2.3(0.9–3.7) | 1.8 (1.1–2.4) | 1.7 (0.4–3.1) | 1.8 (1.0–2.5) | ||
| ALL | 8.4 (6.7–10.1) | 6.4 (3.9–8.9) | 7.7(6.3–9.0) | 5.2 (4.3–6.1) | 4.7 (3.8–5.5) | 4.8 (4.3–5.3) | ||
| Esteller et al. (31) | AA/GBM | ALL (RT+BCNU) | MGMTu/MGMTm: HR = 9.5 (95% CI: 3.0–42.7, p < 0.001) |
MGMTu/MGMTm: HR = 10.8 (95% CI: 4.4–30.8, p < 0.001) |
||||
| Hegi et al. (32) | GBM | ALL (RT+TMZ after surgery) |
MGMTu/MGMTm: The risk of death within 18 months after surgery: 92% vs. 38%; p = 0.002 | NG | ||||
| Everhard et al. (33) | LGG | ALL (TMZ) | NG | 29.5 (21.5–n.r.) | 6 (5–n.r.) | 28 (20–n.r.) | ||
| Pandith et al. (37) | Gliomas | RT+TMZ | 40.1 (29.8–50.3) | 6.8 (3.8–9.6) | 43.4 (32.5–54.1) | 23.9 (20.0–27.7) | 3.2 (0.6–5.8) | 25.8 (21.9–29.6) |
| Malmstrom et al. (38) | GBM (age≥60) | TMZ | 9.7 (8.0–11.4) | 6.8 (5.9–7.7) | 8.3 (7.1–9.5) | NG | ||
| Standard RT (60 Gy) | 8.2 (6.6–9.9)※ | 7.0 (5.7–8.3)※ | 6.0 (5.1–6.8) | |||||
| Hypofractioned RT (34 Gy) | 7.5 (6.5–8.6) | |||||||
| ALL | 9.0 (8.0–10.0) | 6.9 (5.9–7.9) | NG | |||||
| Wick et al. (39) | AA/GBM (age ≥ 65) | TMZ | n.r. (10.1–n.r.) | 7 (5.7–8.7) | 8.6 (7.3–110.2) | 8.4 (5.5–11.7) | 3.3 (3.0–3.5) | 3.3 (3.2–4.1) |
| RT | 9.6 (6.4–n.r.) | 10.4 (8–11.6) | 9.6 (8.2–10.8) | 4.6 (4.2–5.0) | 4.6 (3.7–6.3) | 4.7 (4.2–5.2) | ||
| ALL | 11.9 (9.0–n.r.) | 8.2 (7.0–10.0) | NG | 5.7 (5.0–7.4) | 3.5 (3.3–3.7) | NG | ||
| van den Bent et al. (40) | AOD/AOA (≥25% oligodendroglia elements) | RT RT+PVC | 59.3 (30.0–66.2) n.r. (n.r.) | 12.3 (11.5–28.5) 19.0 (12.3–34.5) | NG | 17.9 (11.9–43.4) 49.0 (19.1–71.2) | 7.8 (7.1–17.6) 10.5 (5.2–23.0) | NG |
| Wick et al. (41) | Anaplastic gliomas (WHO III) |
NG | MGMTu/MGMTm: | |||||
| RT | 72.1 (n.r.) | HR = 2.0 (95% CI: 1.1–3.6, p < 0.03) | 30.6 (16.3–42.8) | |||||
| TMZ/PCV | 82.6 (n.r.) | HR = 2.7 (95% CI: 1.4–5.1, p < 0.003) | 31.9 (21.1–37.3) | |||||
| Gilbert et al. (42) | GBM | Standard dose TMZ | 21.4 (17.6–29.0) | 14.6 (13.2–16.5) | 16.6 (14.9–18.0) | 6.5 (4.1–9.6) | 5.1 (4.3–5.7) | 5.5 (4.7–6.1) |
| Dense dose TMZ | 20.2 (15.4–25.1) | 13.3 (12.3–14.3) | 14.9 (13.7–16.5) | 10.1 (7.9–12.4) | 6.0 (5.5–6.5) | 6.7 (6.2–7.7) | ||
| ALL | 21.2 (17.9–24.8) | 14.0 (12.9–14.7) | NG | 8.7 (6.6–11.2) | 5.7 (5.1–6.1) | NG | ||
, included other treatments: BCNU alone or supportive care; ※, standard RT and hypofractioned RT is grouped together; GBM, glioblastoma; LGG, low-grade gliomas; AA, anaplastic astrocytoma; AOD, anaplastic oligodendroglia tumors; AOA, anaplastic oligoastrocytoma; RT, radiotherapy; TMZ, temozolomide; BCNU, carmustine; PCV, procarbazine, lomustine, and vincristine; OS, median overall survival; PFS, median progression-free survival; MGMTm, MGMT promoter methylated status; MGMTu, MGMT promoter unmethylated status; NG, not given; n.r., not reached; HR, hazard ratio; 95%CI, 95 percent confidence interval.